Список литературы к Главе 20

1. Hallek M., Fischer K., Fingerle­Rowson G., Fink A.M., Busch R., Mayer J. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376. P. 1164–1174.

2. Stilgenbauer S., Schnaiter A., Paschka P., Zenz T., Rossi M., Dohner K. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123. P. 3247–3254.

3. Fischer K., Cramer P., Busch R., Böttcher S., Bahlo J., Schubert J. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group // J. Clin. Oncol. 2012. Vol. 30. P. 3209–3216.

4. Hallek M., Cheson B.D., Catovsky D., Caligaris­Cappio F., Dighiero G., Dohner H. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute­Working Group 1996 guidelines // Blood. 2008. Vol. 111. P. 5446–5456.

5. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343. P. 1910–1916.

6. Zenz T., Eichhorst B., Busch R., Denzel T., Häbe S., Winkler D. et al. TP53 mutation and survival in chronic lymphocytic leukemia // J. Clin. Oncol. 2010. Vol. 28. P. 4473–4479.

7. Rossi D., Cerri M., Deambrogi C., Sozzi E., Cresta S., Rasi S. et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness // Clin. Cancer Res. 2009. Vol. 15. P. 995–1004.

8. Zenz T., Krober A., Scherer K., Habe S., Buhler A., Benner A. et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long­term follow­up // Blood. 2008. Vol. 112. P. 3322–3329.

9. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V. et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage // Blood. 2009. Vol. 114. P. 5307–5314.

10. Zainuddin N., Murray F., Kanduri M., Gunnarsson R., Smedby K.E., Enblad G. et al. TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia // Leuk. Res. 2011. Vol. 35. P. 272–274.

11. Dicker F., Herholz H., Schnittger S., Nakao A., Patten N., Wu L. et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype // Leukemia. 2009. Vol. 23. P. 117–124.

12. Zenz T., Häbe S., Denzel T., Mohr J., Winkler D., Bühler A. et al. Detailed analysis of p53 pathway defects in fludarabine­refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53­p21 dysfunction, and miR34a in a prospective clinical trial // Blood. 2009. Vol. 114. P. 2589–2597.

13. Stengel A., Kern W., Haferlach T., Meggendorfer M., Fasan A., Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases // Leukemia. 2017. Vol. 31. P. 705–711.

14. Gonzalez D., Martinez P., Wade R., Hockley S., Oscier D., Matutes E. et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial // J. Clin. Oncol. 2011. Vol. 29. P. 2223–2229.

15. Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J.F., Munir T. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open­label, phase 2 study // Lancet Oncol. 2016. Vol. 17. P. 768–778.

16. O’Brien S., Jones J.A., Coutre S.E., Mato A.R., Hillmen P., Tam C. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE­17): a phase 2, open­label, multicentre study // Lancet Oncol. 2016. Vol. 17. P. 1409–1418.

17. Brown J.R., Byrd J.C., Coutre S.E., Benson D.M., Flinn I.W., Wagner­Johnston N.D. et al. Idelalisib, an inhibitor of phosphatidylinositol 3­kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia // Blood. 2014. Vol. 123. P. 3390–3397.

18. Pospisilova S., Gonzalez D., Malcikova J., Trbusek M., Rossi D., Kater A.P. et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia // Leukemia. 2012. Vol. 26. P. 1458–1461.

19. Malcikova J., Stano­Kozubik K., Tichy B., Kantorova B., Pavlova S., Tom N. et al. Detailed analysis of therapy­driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia // Leukemia. 2015. Vol. 29. P. 877–885.

20. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia // Cell. 2013. Vol. 152. P. 714–726.

21. Nadeu F., Delgado J., Royo C., Baumann T., Stankovic T., Pinyol M. et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia // Blood. 2016. Vol. 127. P. 2122–2130.

22. Rossi D., Khiabanian H., Spina V., Ciardullo C., Bruscaggin A., Famà R. et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia // Blood. 2014. Vol. 123. P. 2139–2147.

23. Zenz T., Habe S., Denzel T., Winkler D., Dohner H., Stilgenbauer S. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance // Leukemia. 2008. Vol. 22. P. 2257–2258.

24. Lin M.T., Mosier S.L., Thiess M., Beierl K.F., Debeljak M., Tseng L.H. et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next­generation sequencing // Am. J. Clin. Pathol. 2014. Vol. 141. P. 856–866.

25. Oh E., Choi Y.L., Kwon M.J., Kim R.N., Kim Y.J., Song J.Y. et al. Comparison of accuracy of whole­exome sequencing with formalin­fixed paraffin­embedded and fresh frozen tissue samples // PLoS One. 2015. Vol. 10. Article ID e0144162.

26. Williams C., Pontén F., Moberg C., Söderkvist P., Uhlén M., Pontén J. et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens // Am. J. Pathol. 1999. Vol. 155. P. 1467–1471.

27. Edlund K., Larsson O., Ameur A., Bunikis I., Gyllensten U., Leroy B. et al. Data­driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors // Proc. Natl Acad. Sci. USA. 2012. Vol. 109. P. 9551–9556.

28. Lykke­Andersen S., Jensen T.H. Nonsense­mediated mRNA decay: an intricate machinery that shapes transcriptomes // Nat. Rev. Mol. Cell Biol. 2015. Vol. 16. P. 665–677.

29. Leroy B., Ballinger M.L., Baran­Marszak F., Bond G.L., Braithwaite A., Concin N. et al. Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice // Cancer Res. 2017. Vol. 77. P. 1250–1260.

30. Pal K., Bystry V., Reigl T., Demko M., Krejci A., Touloumenidou T. et al. GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data // Bioinformatics. 2017. Vol. 33. P. 3802–3804.

31. Kantorova B., Malcikova J., Smardova J., Pavlova S., Trbusek M., Tom N. et al. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods // Tumour Biol. 2015. Vol. 36. P. 3371–3380.

32. Lazarian G., Tausch E., Eclache V., Sebaa A., Bianchi V., Letestu R. et al. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes // Int. J. Cancer. 2016. Vol. 139. P. 1759–1763.

33. Sutton L.A., Ljungström V., Mansouri L., Young E., Cortese D., Navrkalova V. et al. Targeted next­generation sequencing in chronic lymphocytic leukemia: a high­throughput yet tailored approach will facilitate implementation in a clinical setting // Haematologica. 2015. Vol. 100. P. 370–376.

34. Jethwa A., Hüllein J., Stolz T., Blume C., Sellner L., Jauch A. et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia // Br. J. Haematol. 2013. Vol. 163. P. 496–500.

35. Akbari M., Hansen M.D., Halgunset J., Skorpen F., Krokan H.E. Low copy number DNA template can render polymerase chain reaction error prone in a sequence­dependent manner // J. Mol. Diagn. 2005. Vol. 7. P. 36–39.

36. Hiatt J.B., Pritchard C.C., Salipante S.J., O’Roak B.J., Shendure J. Single molecule molecular inversion probes for targeted, high­ accuracy detection of low­frequency variation // Genome Res. 2013. Vol. 23. P. 843–854.

37. Kinde I., Wu J., Papadopoulos N., Kinzler K.W., Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing // Proc. Natl Acad. Sci. USA. 2011. Vol. 108. P. 9530–9535.

38. Chen G., Mosier S., Gocke C.D., Lin M.T., Eshleman J.R. Cytosine deamination is a major cause of baseline noise in next­generation sequencing // Mol. Diagn. Ther. 2014. Vol. 18. P. 587–593.

39. den Dunnen J.T., Dalgleish R., Maglott D.R., Hart R.K., Greenblatt M.S., McGowan­Jordan J. et al. HGVS recommendations for the description of sequence variants: 2016 update // Hum. Mutat. 2016. Vol. 37. P. 564–569.

40. Bouaoun L., Sonkin D., Ardin M., Hollstein M., Byrnes G., Zavadil J. et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data // Hum. Mutat. 2016. Vol. 37. P. 865–876.

41. Leroy B., Anderson M., Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade // Hum. Mutat. 2014. Vol. 35. P. 672–688.

42. Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T. et al. Analysis of protein­coding genetic variation in 60,706 humans // Nature. 2016. Vol. 536. P. 285–291.

43. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential // Nat. Genet. 2003. Vol. 33. P. 357–365.

44. Kochethu G., Delgado J., Pepper C., Starczynski J., Hooper L., Krishnan S. et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia // Leuk. Res. 2006. Vol. 30. P. 1113–1118.

45. Majid A., Richards T., Dusanjh P., Kennedy D.B., Miall F., Gesk S. et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome // Br. J. Haematol. 2011. Vol. 153. P. 533–535.

46. Dong H.J., Fang C., Wang L., Fan L., Xu J., Wu J.Z. et al. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia // Med. Oncol. 2014. Vol. 31. P. 908.

47. Sturm I., Bosanquet A.G., Hummel M., Dörken B., Daniel P.T. In B­CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis // BMC Cancer. 2005. Vol. 5. P. 105.

48. Soussi T., Leroy B., Taschner P.E. Recommendations for analyzing and reporting TP53 gene variants in the high­throughput sequencing era // Hum. Mutat. 2014. Vol. 35. P. 766–778.

49. Kalia S.S., Adelman K., Bale S.J., Chung W.K., Eng C., Evans J.P. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics // Genet. Med. 2017. Vol. 19. P. 249–255.